Immunome, Inc.
NASDAQ:IMNM
12.54 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 14.018 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.728 | 0.631 | 0.755 | 0.755 | 0.615 | 0.521 |
| Gross Profit
| 13.29 | -0.631 | -0.755 | -0.755 | -0.615 | -0.521 |
| Gross Profit Ratio
| 0.948 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 103.163 | 23.272 | 14.11 | 7.486 | 8.823 | 6.877 |
| General & Administrative Expenses
| 19.657 | 13.629 | 11.094 | 4.775 | 1.525 | 0.866 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 19.657 | 13.629 | 11.094 | 4.775 | 1.525 | 0.866 |
| Other Expenses
| 23.089 | 0 | 0.503 | 0 | 0 | 0 |
| Operating Expenses
| 122.82 | 36.901 | 25.204 | 12.261 | 10.348 | 7.743 |
| Operating Income
| -109.53 | -36.901 | -25.204 | -12.261 | -10.348 | -7.743 |
| Operating Income Ratio
| -7.814 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 2.724 | 0.005 | 0.493 | -5.576 | -0.096 | -0.102 |
| Income Before Tax
| -106.806 | -36.896 | -24.711 | -17.837 | -10.444 | -7.845 |
| Income Before Tax Ratio
| -7.619 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.56 | 0.617 | -0.242 | -0.717 | 0.106 | 0.039 |
| Net Income
| -106.806 | -37.513 | -24.469 | -17.12 | -10.55 | -7.845 |
| Net Income Ratio
| -7.619 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -5.38 | -3.09 | -2.12 | -5.05 | -1.84 | -1.79 |
| EPS Diluted
| -5.38 | -3.09 | -2.12 | -5.05 | -1.84 | -1.79 |
| EBITDA
| -108.802 | -36.27 | -24.701 | -12.261 | -9.723 | -7.183 |
| EBITDA Ratio
| -7.762 | 0 | 0 | 0 | 0 | 0 |